Meta AnalysisID 333
核桃摄入与健康：2017年至今发表的队列研究和随机对照试验的系统评价
CRD42021225340
• What is the association between walnut consumption and public health outcomes of relevance in higher/middle income countries (specifically all cause mortality, type 2 diabetes, CVD, metabolic syndrome, obesity, cancer,
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Herb: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 333
- Evidence Id
- 8891
- Core Evidence Id
- 8891
- Source Meta Analysis Id
- 313
- Herb2 Meta Analysis Id
- HBMA000313
- Crd Id
- CRD42021225340
- Title
- Walnut consumption and health - a systematic review of cohort studies and randomised controlled trials published from 2017-present
- Review Question
- • What is the association between walnut consumption and public health outcomes of relevance in higher/middle income countries (specifically all cause mortality, type 2 diabetes, CVD, metabolic syndrome, obesity, cancer, neurological and mental health disorders, musculoskeletal disorders, gastrointestinal disorders and maternal disorders)? • What is the effect of walnut consumption on risk of all cause mortality, type 2 diabetes, CVD, metabolic syndrome, obesity, cancer, neurological and mental health disorders, musculoskeletal disorders, gastrointestinal disorders and maternal disorders?
- Study Type Included
- We will include cohort studies and randomised controlled trials (placebo-controlled and crossover) with the amount and frequency of walnuts clearly defined. Cross-sectional, animal, in vitro and ex vivo studies will be excluded.
- Condition Being Studied
- The main public health outcomes of relevance in higher/middle income countries (assessed by contribution to deaths and DALYs identified by the GBD study and the WHO) that may be affected or prevented by diet. Specifically: all cause mortality, type 2 diabetes, CVD, metabolic syndrome, obesity, cancer, neurological and mental health disorders, musculoskeletal disorders, gastrointestinal disorders and maternal disorders.
- Participant
- Studies carried out in humans will be included, specifically adults and children both from within the general population and those with existing health conditions (e.g. type 2 diabetes, CVD).
- Animal
- Human Disease Modelled
- Intervention
- Studies of at least 3 weeks duration, specifically examining the consumption of walnuts (whole walnuts or pieces or 100% walnut butter), where the effect of walnut consumption can be isolated from other food sources or interventions such as physical activity programmes, will be included. Studies providing walnuts as part of a nut mixture will be excluded. Studies considering/providing only walnut components (e.g. walnut oil, walnut extracts, walnut husk) will be excluded.
- Comparator Control
- No walnut consumption (any comparator, excluding drugs) or lower walnut consumption.
- Main Outcome
- Cohort studies: hard endpoints and intermediary measures including: • all cause mortality, • diabetes (type 2), • CVD, • metabolic syndrome, • obesity, • cancer, • neurological and mental health disorders, • musculoskeletal disorders, • gastrointestinal disorders, • maternal disorders Randomised controlled trials: risk markers including: • markers of ageing e.g. telomere length, physical function • insulin sensitivity e.g. HOMA-IR • blood lipids e.g. TC, TAG, HDL, LDL • blood pressure • vascular function e.g. FMD • inflammatory markers e.g. CRP, • oxidative stress e.g. oxidised LDL • haemostatic markers e.g. von Willebrand factor (vWF) • body weight and composition e.g. BMI • cancer markers e.g. changes in gene expression • markers of cognitive function and mental health e.g. cognitive tests • markers of bone and muscle health e.g. bone mineral density • markers of gut health e.g. gut microbial diversity • markers of maternal health e.g. gestational diabetes Studies that do not include any of the main or additional outcomes will be excluded. Listed outcomes are not required to be the primary outcome in order for a study to be included. Measures of effect The effect measures reported for the outcomes of interest in the included studies will be documented.
- Outcome Measure
- Additional Outcome
- Adverse events. Measures of effect Not applicable.
- Study Method
- Epidemiologic, Intervention, Narrative synthesis, Systematic review
- Keyword
- Cohort Studies; Humans; Juglans; Nuts; Physiological Phenomena; Publications
- Contact
- Stacey Lockyer [email protected]
- Organisational Affiliation
- British Nutrition Foundation nutrition.org.uk
- Funding Source
- The California Walnut Commission
- Other Selection Criteria
- Final Publication
- Lockyer S, de la Hunty AE, Steenson S, Spiro A, Stanner SA. Walnut consumption and health outcomes with public health relevance—a systematic review of cohort studies and randomized controlled trials published from 2017 to present. Nutrition Reviews. 2023 Jan;81(1):26-54. https://academic.oup.com/nutritionreviews/article/81/1/26/6651942
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- England
- Review Stage
- Review Completed published
- First Submission Date
- 2020-12-11
- Registration Date
- 2021-01-08
- Anticipated Start Date
- 2020-12-09
- Anticipated Completion Date
- 2022-04-01
- Title Cn
- 核桃摄入与健康：2017年至今发表的队列研究和随机对照试验的系统评价
- Title En
- Walnut consumption and health - a systematic review of cohort studies and randomised controlled trials published from 2017-present
- Bilingual Status
- complete